VQW-765

VQW-765 (AQW-051) is a selective and orally active alpha-7 nicotinic acetylcholine receptor (α7-nAChR) agonist with a pKD value of 7.56 to recombinantly expressed human α7-nAChR. VQW-765 shows anxiolytic-like effect in vivo. VQW-765 can be used for the research of anxiety disorder and acute performance anxiety[1].

Product Specifications

CAS Number

[669770-29-0]

Product Name Alternative

AQW-051

UNSPSC

12352005

Hazard Statement

H315, H319, H335

Target

NAChR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/vqw-765.html

Purity

99.58

Solubility

DMSO : 16.67 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

CC1=CC=C(C2=CC=C(O[C@H]3CN4CCC3CC4)C=N2)C=C1

Molecular Formula

C19H22N2O

Molecular Weight

294.40

Precautions

H315, H319, H335

References & Citations

[1]Feuerbach D, et al. AQW051, a novel, potent and selective α7 nicotinic ACh receptor partial agonist: pharmacological characterization and phase I evaluation. Br J Pharmacol. 2015 Mar;172 (5) :1292-304.